John J. Sperzel III - 20 Feb 2023 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)

Role
Chairman and CEO, Director
Signature
/s/ John Sprague, Attorney-in-fact
Issuer symbol
TTOO
Transactions as of
20 Feb 2023
Net transactions value
-$6,179
Form type
4
Filing time
09 Mar 2023, 15:00:07 UTC
Previous filing
11 Apr 2022
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTOO Common Stock Options Exercise +16,000 +361% 20,435 20 Feb 2023 Direct F1
transaction TTOO Common Stock Sale $4,469 -6,875 -34% $0.6500 13,560 22 Feb 2023 Direct F2
transaction TTOO Common Stock Options Exercise +6,667 +49% 20,227 24 Feb 2023 Direct F1
transaction TTOO Common Stock Sale $1,710 -2,898 -14% $0.5900 17,329 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TTOO Restricted Stock Units Options Exercise $0 -16,000 -33% $0.000000 32,000 20 Feb 2023 Common Stock 16,000 Direct F1, F3
transaction TTOO Restricted Stock Units Options Exercise $0 -6,667 -50% $0.000000 6,667 20 Feb 2023 Common Stock 6,667 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on May 20, 2021.
F3 On February 20, 2022 the reporting person was granted 48,000 RSU's that vest in three equal annual installments commencing on February 20, 2023
F4 On February 24, 2021 the reporting person was granted 20,000 RSU's that vest in three equal annual installments commencing on February 24, 2022.